Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Tri-Heal Max Protocol Overview, Dosing & Safety | Peptide Database

Tri-Heal Max Protocol (Tri-Heal Max) High-Dose Three-Peptide Healing Blend Community Research Join others researching Tri-Heal Max Protocol — share findings, ask questions, and learn from real experiences Tri-Heal Max is an enhanced healing peptide blend featu

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Tri-Heal Max Protocol (Tri-Heal Max)

High-Dose Three-Peptide Healing Blend

Community Research

Join others researching Tri-Heal Max Protocol — share findings, ask questions, and learn from real experiences

Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.

Each peptide contributes distinct healing pathways: TB-500 (Thymosin Beta-4) enhances cellular migration, promotes actin polymerization, and supports blood vessel formation for tissue repair; BPC-157 upregulates growth factors (VEGF, EGF), accelerates wound healing, and provides gastrointestinal protection; KPV (alpha-MSH fragment) inhibits the NF-κB inflammatory pathway, reduces pro-inflammatory cytokines, and may improve injection site tolerability. Together, they address inflammation, tissue regeneration, and cellular repair.

Molecular Data

Complex or non-standard sequence format

Research Indications

Higher TB-500 dose targets more severe tissue damage requiring enhanced repair.

TB-500 promotes muscle fiber repair and cellular migration.

Combined collagen support and growth factor upregulation.

Multi-modal support for surgical wound recovery.

KPV component reduces post-surgical inflammatory response.

Enhanced tissue remodeling may reduce scar formation.

Accelerated return to activity after sports injuries.

Address accumulated tissue damage from repetitive stress.

Dosing Protocols

Subcutaneous injection is the primary delivery method. Can inject near injury site or systemically. The higher TB-500 content makes this suitable for more significant healing needs.

Conservative healing

200-300mcg total blend

Once daily

SubQ

Standard healing protocol

300-500mcg total blend

Intensive healing (acute injury)

500mcg total blend

Once daily for first 2 weeks, then reduce

SubQ near injury site

Cycling protocol

Per standard dosing

4-6 weeks on, 2-4 weeks off

Reconstitution Instructions

Tri-Heal Max 45mg vial

Bacteriostatic water (2-4mL)

Insulin syringes

Alcohol prep pads

1 Clean vial top with alcohol pad

2 Add 2mL bacteriostatic water (creates 22.5mg/mL)

3 Gently swirl - do not shake

4 Solution should appear clear

5 Label with date and concentration

6 Store refrigerated immediately

7 Use within 4-6 weeks

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Injection site reactions (KPV may help reduce these)

Mild fatigue during healing

Temporary redness at injection site

Stop Signs - Discontinue if:

Severe injection site reactions or signs of infection

Allergic reactions (rash, swelling, difficulty breathing)

Unusual bleeding or bruising

Worsening of underlying conditions

Contraindications

No clinical trials on this three-peptide combination

Active cancer (theoretical concern with growth-promoting peptides)

Pregnancy or breastfeeding

Active infection at injection site

Quality Checklist

Good Signs

Third-party testing confirming all three components

Certificate of Analysis with ratios verified

Reputable research supplier

Proper cold chain shipping

Warning Signs

Research-only status - not approved for human use

Batch variability possible in ratios

Bad Signs

No Certificate of Analysis

Cannot verify TB-500:BPC:KPV ratio

Discolored or particulate solution

Frequently Asked Questions

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, major surgery recovery, or chronic tissue damage requiring enhanced regenerative support beyond standard healing stacks.

Is KPV necessary in Tri-Heal Max or is it just TB-500 and BPC-157?

KPV adds anti-inflammatory effects by inhibiting the NF-κB pathway and reducing pro-inflammatory cytokines, complementing TB-500's cell migration and BPC-157's growth factor upregulation. KPV may also reduce injection site reactions, making the three-peptide blend more tolerable than two-peptide combinations.

How long should someone use Tri-Heal Max and can it be cycled indefinitely?

Standard protocol is 4-6 weeks of active healing, then 2-4 weeks off to assess tissue recovery. Cycling prevents tolerance and allows natural healing processes to consolidate gains. Long-term indefinite use isn't studied - rotate on/off cycles or reduce to maintenance (1-2x weekly) after acute phase resolves.

Can Tri-Heal Max be used for cosmetic healing (scars, skin texture) or just injury recovery?

Tri-Heal Max's multi-modal healing could theoretically support scar reduction and skin quality improvement through enhanced collagen remodeling and angiogenesis. However, clinical data is limited to musculoskeletal injuries - cosmetic use is experimental and requires realistic expectations about scar improvement potential.

References

TB-500 promotes cell migration, blood vessel formation, and wound healing through actin modulation.

BPC-157 upregulates growth factors and accelerates healing of various tissue types.

KPV (alpha-MSH 11-13) inhibits NF-κB pathway and reduces pro-inflammatory cytokines.

Specific three-peptide combination has not been studied in clinical trials.

Related Peptides

Complementary healing mechanisms; GHK-Cu adds copper-peptide benefits.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Kisspeptin — share findings, ask questions, and learn from real experiences Kisspeptin acts as a master regulator of the reproductive system, stimulating GnRH neurons essential for puberty, fertility, and reproductive function. Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.

Source: peptide-db.com ↗

Community Research

Join others researching Clascoterone — share findings, ask questions, and learn from real experiences Clascoterone (cortexolone 17-alpha-propionate) is a first-in-class topical androgen receptor inhibitor developed by Cassiopea SpA. In August 2020, the FDA approved Winlevi (clascoterone cream 1%) for the treatment of acne vulgaris in patients aged 12 and older, making it the first new mechanism of action for acne treatment in nearly four decades and the first topical anti-androgen approved for acne in the United States. Clascoterone is also under development as Breezula (clascoterone solution 7.5%) for androgenetic alopecia, where it has completed Phase 3 clinical trials. The compound works by competitively inhibiting androgen receptor activation at the site of application -- the sebaceous gland for acne and the hair follicle for androgenetic alopecia -- without producing the systemic anti-androgenic effects associated with oral anti-androgens such as spironolactone or cyproterone acetate. Its steroidal structure allows it to fit precisely into the androgen receptor binding pocket, and its rapid local metabolism to cortexolone (an inactive metabolite) limits systemic exposure. This pharmacological profile makes clascoterone suitable for use in both men and women, unlike systemic anti-androgens which carry risks of feminization in male patients. Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia). By occupying the AR binding site, clascoterone prevents dihydrotestosterone (DHT) and testosterone from activating the receptor and initiating the downstream signaling cascade that drives sebum overproduction and hair follicle miniaturization. Structurally, clascoterone is a synthetic derivative of cortexolone (11-deoxycortisol), modified with a 17-alpha-propionate ester. This structural design serves two purposes: the steroidal backbone provides high binding affinity for the androgen receptor, while the ester group is rapidly cleaved by local esterases in the skin, converting clascoterone to cortexolone, which has negligible androgen receptor binding. This built-in metabolic inactivation ensures that any compound reaching systemic circulation is pharmacologically inactive, confining the anti-androgenic effect to the treatment site. In clinical studies, clascoterone showed no meaningful impact on systemic hormone levels including testosterone, DHT, luteinizing hormone, or follicle-stimulating hormone at therapeutic doses, confirming its local mechanism of action.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Pramipexole is administered orally as a tablet, available in immediate-release and extended-release formulations. For prolactin management in bodybuilding contexts, the immediate-release tablet is standard. Oral bioavailability is greater than 90%, and absorption is not significantly affected by food. The relatively short half-life of approximately 8 hours requires daily dosing, typically taken at bedtime to minimize daytime drowsiness and nausea. Dosing must be titrated upward slowly from 0.125mg to the target dose over 1-2 weeks to reduce gastrointestinal and CNS side effects. Prolactin management during 19-nor cycle (starting dose) 0.125mg Once daily at bedtime Oral Prolactin management during 19-nor cycle (standard dose) 0.25mg Prolactin management during 19-nor cycle (higher dose if needed) 0.5mg Restless Legs Syndrome (medical) 0.125-0.5mg Once daily, 2-3 hours before bedtime

Source: peptide-db.com ↗
Side effects

Does rosuvastatin have the same muscle pain side effects as other statins?

Rosuvastatin's hydrophilic nature theoretically gives it lower myopathy risk than lipophilic statins like atorvastatin, but real-world incidence is similar (3-5% true statin myopathy). Muscle soreness from gym training can feel amplified on any statin, but serious rhabdomyolysis is rare at doses used for AAS lipid management.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →